The relationship between serum immunoglobulin levels and pulmonary involvement in systemic sclerosis

Journal of Rheumatology

Volumn 27, Issue 5, 2000, Pages 1207-1214

  Yuhara, Takamichi ^a   Takemura, Hiroyuki ^a   Akama, Takao ^a   Yamane, Kazuhide ^a   Sumida, Takayuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Immunoglobulin; Pulmonary function test; Pulmonary involvement systemic sclerosis

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PENICILLAMINE;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; LUNG FUNCTION TEST; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ADULT; FEMALE; HUMANS; IMMUNOGLOBULINS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; TIME FACTORS;

EID: 0034104789     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lee P, Langevitz P, Alderdice CA, et al. Mortality in systemic sclerosis (scleroderma). Q J Med 1992;82:139-48.
2. Peters-Golden M, Wise R, Hochberg MC, Stevens MB, Wigley FM. Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis. Am J Med 1984;77:1027-34.
3. Silver RM, Warrick JH, Kimella MB, Staudt LS, Baumann MH. Strange C. Cyclosphosphamide and law-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 1993;20:838-44.
4. Kallenberg CG, Jansen HM, Elema JD, The TH. Steroid-responsive interstitial pulmonary disease in systemic sclerosis. Monitoring by bronchoalveolar lavage. Chest 1984;86:489-92.
5. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum 1998;41:1215-20.
6. Steen VD, Lanz JJ, Conte C, Owens GR, Medsger TA. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994;37:1290-6.
7. Varai G, Earle L, Jimenez SA, Steiner RM, Varga J. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol 1998;25:1325-9.
8. Akesson A, Scheja A, Lundin A, Wollheim FA. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 1994;37:729-35.
9. Steen VD, Owens GR, Redmond C, Rodnan GP, Medsger TA. The effect of D-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum 1985;28:882-8.
10. Behr J, Vogelmeier C, Beinert T, et al. Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung. Am J Respir Crit Care Med 1996;154:400-6.
11. Silver RM, Miller S, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med 1990;88:470-6.
12. Peters-Golden M, Wise R, Schneider P, Hochberg M, Stevens MB, Wigley F. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Medicine (Baltimore) 1984;63:221-31.
13. Blaese RM, Grayson J, Steinberg AD. Increased immunoglobulin-secreting cells in the blood of patients with active systemic lupus erythematosus. Am J Med 1980;69:345-50.
14. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis. Arthritis Rheum 1980;23:581-90.
15. LeRoy E, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis) classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
16. Douvas A, Achten M, Tan E. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 1979;254:10514-22.
17. Tan E, Rodnan G, Garcia I, Moroi Y, Fitzler M. Diversity of untinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 1980;23:617-25.
18. Steen V, Conte C, Owens G, Medsger T. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;27:1283-90.
19. Nishioka K, Katayama I, Kondo H, et al. Epidemiological analysis of prognosis of 496 Japanese patients with progressive systemic sclerosis. J Dermatol 1996;23:677-82.
20. Kuwana M, Kaburagi J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994;37:75-8.3.
21. Farber SJ, Bole GG. Antibodies to components of extractable nuclear antigen. Clinical characteristics of patients. Arch Intern Med 1976;136:425-31.
22. Chatterjee S, Price B. Regression analysis by example. 2nd edition. New York: John Wiley & Sons; 1991.
23. Morelli S, Barbieri C, Sgreccia A, et al. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 1996;24:81-5.
24. Kane G, Varga J, Conant E, Spirn P, Jimenez S, Fish J. Lung involvement in systemic sclerosis (scleroderma): relation to classification based on extent ot skin involvement. Respir Med 1996;90:223-30.
25. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515-24.
26. Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997;40:1229-36.
27. Crestani B, Seta N, De Bandt M, et al. Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement. Am J Respir Crit Care Med 1994;149:1260-5.
28. Hasegawa M, Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998;25:308-13.
29. Silver RM, Metcalf JF, Stanley JH, LeRoy EC. Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage. Arthritis Rheum 1984;27:1254-62.
30. Silver RM, Metcalf JF, LeRoy EC. Interstitial lung disease in scleroderma: immune complexes in sera and bronchoalveolar lavage fluid. Arthritis Rheum 1986;29:525-31.
31. Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis 1991;144:706-13.
32. Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM. Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997;40:743-51.
33. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum tumor necrosis factor-alpha in patients with systemic sclerosis with pulmonary fibrosis. J Rheumatol 1997;24:663-5.
34. Jelinek DF, Lipsky PE. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1. J Immunol 1987;139:2970-6.
35. Miyazaki Y, Araki K, Vesin C, et al. Expression of a tumor necrosis factor-alpha transgene in murine lung causes lymphocytic and fibrosing alveolitis. A mouse model of progressive pulmonary fibrosis. J Clin Invest 1995;96:250-9.
36. Steen VD, Engel EE, Charley MR, Medsger TA. Soluble serum interleukin 2 receptors in patients with systemic sclerosis. J Rheumatol 1996;23:646-9.
37. Degiannis D, Seibold JR, Czarnecki M, Raskova J, Raska KJ. Soluble interleukin-2 receptors in patients with systemic sclerosis: clinical and laboratory correlations. Arthritis Rheum 1990;33:375-80.
38. Kikuchi K, Kubo M, Sato S, Fujimoto M, Tamaki K. Serum tissue inhibitor of metalloproteinases in patients with systemic sclerosis. J Am Acad Dermatol 1995;33:973-8.
39. Meunier P, Filipe P, Emerit I, Freitas J, Guerra Rodrigo F, Manso C. Adenosine deaminase in progressive systemic sclerosis. Acta Derm Venereol 1995;75:297-9.
40. Denton CP, Bickerstaff MC, Shiwen X, et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995;34:1048-54.
41. Troshinsky MB, Kane GC, Varga J, et al. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med 1994;121:6-10.